- Home
- AMRN vs ANNX Comparison
AMRN vs ANNX Comparison
Compare AMRN & ANNX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AMRN
- ANNX
- Stock Information
- Founded
- AMRN 1989
- ANNX 2011
- Country
- AMRN Ireland
- ANNX United States
- Employees
- AMRN N/A
- ANNX N/A
- Industry
- AMRN Biotechnology: Pharmaceutical Preparations
- ANNX Biotechnology: Pharmaceutical Preparations
- Sector
- AMRN Health Care
- ANNX Health Care
- Exchange
- AMRN Nasdaq
- ANNX Nasdaq
- Market Cap
- AMRN 216.0M
- ANNX 216.1M
- IPO Year
- AMRN 1993
- ANNX 2020
- Fundamental
- Price
- AMRN $11.95
- ANNX $2.30
- Analyst Decision
- AMRN Sell
- ANNX Strong Buy
- Analyst Count
- AMRN 2
- ANNX 4
- Target Price
- AMRN $7.00
- ANNX $12.50
- AVG Volume (30 Days)
- AMRN 75.5K
- ANNX 1.4M
- Earning Date
- AMRN 05-07-2025
- ANNX 05-12-2025
- Dividend Yield
- AMRN N/A
- ANNX N/A
- EPS Growth
- AMRN N/A
- ANNX N/A
- EPS
- AMRN N/A
- ANNX N/A
- Revenue
- AMRN $214,112,000.00
- ANNX N/A
- Revenue This Year
- AMRN N/A
- ANNX N/A
- Revenue Next Year
- AMRN $5.97
- ANNX N/A
- P/E Ratio
- AMRN N/A
- ANNX N/A
- Revenue Growth
- AMRN N/A
- ANNX N/A
- 52 Week Low
- AMRN $7.08
- ANNX $1.29
- 52 Week High
- AMRN $17.58
- ANNX $7.85
- Technical
- Relative Strength Index (RSI)
- AMRN 69.15
- ANNX 62.45
- Support Level
- AMRN $11.27
- ANNX $2.01
- Resistance Level
- AMRN $11.84
- ANNX $2.21
- Average True Range (ATR)
- AMRN 0.50
- ANNX 0.18
- MACD
- AMRN 0.08
- ANNX 0.04
- Stochastic Oscillator
- AMRN 83.83
- ANNX 91.30
About AMRN Amarin Corporation plc
Amarin Corp PLC is a biopharmaceutical company. It is focused on the commercialization and development of therapeutics to improve cardiovascular, or CV, health and reduce CV risk. Its commercialized product includes Vascepa.
About ANNX Annexon Inc.
Annexon Inc is a clinical-stage biopharmaceutical company developing a pipeline of novel therapies for patients with classical complement-mediated disorders of the body, brain, and eye. Its pipeline is based on its platform technology addressing well-researched classical complement-mediated autoimmune and neurodegenerative disease processes, both of which are triggered by aberrant activation of C1q. Its pipeline of product candidates is designed to block the activity of C1q and the entire classical complement pathway in a broad set of complement-mediated diseases. Its product candidates are ANX005, for autoimmune & neurodegenerative disorders; ANX007, for neurodegenerative ophthalmic disorders; ANX1502 for Oral small molecule; and ANX009, for systemic autoimmune diseases.